Hernan Cortes-Funes, M.D., Ph.D.
Dr. Cortes-Funes is currently Chief of Medical Oncology Division at Hospital Universitario 12 de Octubre in Madrid, Spain. His main areas of research interest include: new Anticancer Drug Development, early Clinical Trials (Phase I / II), pharmacology, genetic profiles, retrospective studies on breast cancer, sarcoma, lung and head and neck tumour. He has published over 150 publications and book chapters in the field of Medical Oncology and Chemotherapy with particular emphasis in new drugs development, lung cancer, breast cancer, lymphomas and germ cell tumors.

John Crowley, Ph.D.
John Crowley, Ph.D., brings three decades of exceptional experience in Biostatistics to his role as President and CEO of Cancer Research And Biostatistics (CRAB). Under Dr. Crowley's visionary leadership, CRAB serves as the Statistical Center for the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences, the world's most successful research and treatment facility for myeloma. CRAB also serves as the Statistical Center for the Southwest Oncology Group (SWOG), a federally sponsored clinical research consortium comprised of thousands of cancer centers and investigators across the nation. To serve these groups, Dr. Crowley oversees the study design, protocol development, data management, quality control, data analysis, and statistical research of more than 100 active multi-site clinical cancer trials. He manages a staff of 83 high-level statisticians, data coordinators and other professionals dedicated to conquering cancer through large-scale clinical trials.

Michal Demeure, M.D., M.B.A.
Michael J. Demeure, MD, MBA is currently a Professor of Surgery at the Arizona Health Sciences Center in Tucson, Arizona and a Senior Investigator at TGEN in Phoenix. He received his medical degree from the Hahnemann University College of Medicine in Philadelphia, Pennsylvania. He is the current president of the American Association of Endocrine Surgeons. Dr. Demeure's areas of interest in research are related to surgical oncology and particularly to the molecular oncogenesis of cancers. He has focused primarily on pancreatic cancer and adrenocortical cancer. He is the Biospecimens Tissue Repository Core on a Pancreatic Cancer P-01 grant and is the principal investigator of the TGEN program studying adrenocortical cancer. The goal of both efforts is to identify novel and more effective treatments than are currently available.

Tomislav [Tom] Dragovich, M.D, Ph.D
Assistant Professor of Medicine, Dr. Dragovich, received his pharmacology training at the University of Illinois and his hematology and oncology training at the University of Chicago Pritzkers School of Medicine. Dr. Dragovich's research interest focuses on developing novel treatment approaches for patients with gastrointestinal malignancies (gastric, esophageal, pancreatic, hepatobiliary and colorectal cancers). Dr. Dragovich serves as a Director of the Clinical Core for the Gastrointestinal Cancer SPORE (Specialized Program of Research Excellence) at the Arizona Cancer Center. Dr. Dragovich also serves on the SWOG GI Committee and the ASCO Scientific Committee for GI cancer.

His current clinical/translational research interests include: evaluation of COX-2 inhibitors and receptor tyrosine kinase inhibitors in patients with colorectal and pancreatic malignancies, inhibition of thioredoxin-1 pathway as therapeutic approach in patients with advanced gastrointestinal cancer, and early trials of novel agents in patients with advanced solid tumors and GI malignancies.

Arkadiusz Dudek, M.D., Ph.D.
Dr Dudek is an Assistant Professor and Director of Clinical Trial Office in the Hematology, Oncology and Transplantation (HOT) Division. Dr. Dudek received his M.D. in 1989 from the Medical University of Warsaw, Poland. He received internal medicine residency training in Harrisburg, Pennsylvania and subspecialty training in Hematology, Oncology and Transplantation at the University of Minnesota. He received his Ph.D. from Military Medical Academy of Warsaw in 1998. He joined the Faculty in 1997.

Dr. Dudek's clinical interests include phase I and II clinical trials in solid tumors, pancreatic cancer, malignant melanoma, kidney cancer , and thoracic malignancies. His laboratory research is focused on cancer angiogenesis, tumor vaccines and preclinical novel drug testing.